Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-05T12:29:53.531Z Has data issue: false hasContentIssue false
  • English
  • Français

Neuropeptides and anxiety disorders

Published online by Cambridge University Press:  18 September 2015

H.J.G.M. van Megen ,
J.A. den Boer  and
H.G.M. Westenberg
Get access Rights & Permissions [Opens in a new window]

Summary

In this review article four neuropeptides: adrenocorticotrope hormone (ACTH), corticotrope releasing hormone (CRH), neuropeptide- Y(NPY) and cholecystokinin (CCK) are discussed with respect to their possible role in the pathogenesis of anxiety disorders. First the presumable working mechanism of these peptides in the brain is mentioned. In addition, the relationship of these peptides and anxiety is outlined using neuroanatomical and electrophysiological research data. Subsequently, animal experiments and human research findings are discussed. Most of the research findings so far are obtained from animal data. Only with respect to CCK, there is increasing evidence, also from human studies, that this peptide might play a role in the pathogenesis of anxiety disorders. The putative role of the other peptides remains to be estab lished in future research.

Keywords

anxiety disordersneuropeptidesACTHCRHNPYCCKangststoornissenneuropeptidenACTHCRHNPYCCK
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 4 , Issue 2 , June 1992 , pp. 25 - 30
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1992

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Literatuur

1.Den Boer, JA, Westenberg, HGM.Behavioral, neuro-endocrine and biochemical effects of 5-hydroxytryptophan administration in panic disorder. Psychiat Res 1990; 31: 267–78.CrossRefGoogle Scholar
2.Jenike, MA, Hyman, S, Baer, L, et al.A controlled trial of fluvoxamine in obsessive compulsive disorder: implications for a serotonergic theory. Am J Psychiat 1990; 147: 1209–15.Google ScholarPubMed
3.Wied, D de, Jolles, J.Neuropeptides derived from pro-opiocortin: Behavioral, physiological and neuro-chemical effects. Physiol Rev 1982; 62: 976–1059.CrossRefGoogle Scholar
4.File, SE.Contrasting effects of ORG 2766 and α-MSH on social and exploratory behaviour in the rat. Peptides 1981; 2: 255–60.CrossRefGoogle ScholarPubMed
5.Den Boer, JA, Westerberg, HGM, Vries, H de.The ACTH-(4-9) analog ORG 2766 in anxiety disorders. Peptides 1992; Peptides 1992; 13: 109–12.CrossRefGoogle Scholar
6.Roy-Byrne, PP, Uhde, TW, Post, RM, Gallucci, W, Chrousos, W, Gold, PW.The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiat 1986; 143:896–9.Google ScholarPubMed
7.Holsboer, F, Bardeleben, U von, Heuser, I, Steiger, A.Stimulation response to Corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder. Horm Met res 1987; 16: 80–8.Google ScholarPubMed
8.Thatcher-Britton, K, Morgan, J, Rivier, J, Vale, W, Koob, GF.Chlordiazepoxide attenuates response suppression induced by corticotropin-releasing factor in the conflicttest. Psychopharmacol 1985; 86: 170–4.CrossRefGoogle Scholar
9.Hendry, SHC, Jones, EG, Felipe, J, Schmechel, D, Brandon, C, Emson, PC.Neuropeptide-containing neurons of the cerebral cortex are also GABA-ergic. Proc nat acad sci 1984; 1: 6526–30.CrossRefGoogle Scholar
10.Heilig, M, Söderpalm, B, Engel, JA, Widerlöv, E.Centrally administrated neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacol 1989; 98: 524–9.CrossRefGoogle ScholarPubMed
11.Rehfeld, JF.Neural Cholecystokinin: one or multiple transmitters? Short review. J Neurochem 1985; 44: 1–10.CrossRefGoogle Scholar
12.Moran, TH, Robinson, PH, Goldrich, MS, McHugh, PR.Two brain cholecystokinin receptors: Implications for behavioral actions. Brain Res 1986; 362: 175–9.CrossRefGoogle ScholarPubMed
13.Crowley, JN, Hommer, DW, Skirrboll, LR.Behavioural and neuro-physiological evidence for facilitatory interaction between coexisting transmitters cholecystokinin and dopamine. Neurochem Int 1984; 6: 755–60.CrossRefGoogle Scholar
14.Boden, PR, Woodruff, GN, Pinnock, RD.Pharmacology of cholecystokinin receptor on 5-hydroxytryptamine neurones in the dorsal raphe of the rat. Br J Pharmacol 1991; 102: 635–8.CrossRefGoogle ScholarPubMed
15.Bradwejn, J, Montigny, C de.Benzodiazepines antagonize cholecystokinin induced activation of the rat hippocampal neurons. Nature 1984; 312: 363–4.CrossRefGoogle Scholar
16.Bradwejn, J, Montigny, C de.Antagonism of the cholecystokinin induced activation by benzodiazepine receptor antagonists. Ann NY Acad Sci 1985; 448: 575–80.CrossRefGoogle Scholar
17.Montigny, C de.Cholecystokinin tetrapeptide induces panic like attacks in healthy volunteers. Arch gen Psychiat 1989; 46: 511–7.CrossRefGoogle ScholarPubMed
18.Bradwejn, J, Koszycki, D, Meterissian, G.Cholecystokinin tetrapeptide induces panic attacks in patients with panic disorder. Can J psychiat 1990; 35: 83–5.CrossRefGoogle ScholarPubMed
19.Abelson, LJ, Nesse, RM.Cholecystokinin-4 and panic. Arch gen Psychiat 1990; 47: 395.CrossRefGoogle ScholarPubMed
20.Van Megen, HJGM, Den Boer, JA, Westenberg, HGM. Pentagastrin induced panic attacks in panic disorder patients and volunteers; aangeboden voor publikatie, 1992.Google Scholar